Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for Prevention of Cardiovascular Events in ICH Patients (CoVasc-ICH)
NCT05159219Phase 2Completed
- Sponsor
- Population Health Research Institute
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in intracranial hemorrhage (ICH) comparing Oral Colchicine, 0.5mg once daily with Oral matching placebo, once daily (2 arms). Primary endpoint: Feasibility - Recruitment at 18 months. Started Aug 2022; status: completed.
02
Drugs
colchicine
03
Conditions
intracranial hemorrhage (ICH)
Beyond the preview
Go deeper on NCT05159219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159219.